Ngā hua rapu kaituhi

1

Glybera's Second Act: The Curtain Rises on the High Cost of Therapy mā Seppo Ylä‐Herttuala

I whakaputaina 2015

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Editorial

Tiaki ki tētahi rārangi

I tiakina i:
2

Endgame: Glybera Finally Recommended for Approval as the First Gene Therapy Drug in the European Union mā Seppo Ylä‐Herttuala

I whakaputaina 2012

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Editorial

Tiaki ki tētahi rārangi

I tiakina i:
3

Gene Therapy for Malignant Glioma: Current Clinical Status mā Kalevi Pulkkanen, Seppo Ylä‐Herttuala

I whakaputaina 2005

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Revisão

Tiaki ki tētahi rārangi

I tiakina i:
4

Current Status of Cardiovascular Gene Therapy mā Tuomas T. Rissanen, Seppo Ylä‐Herttuala

I whakaputaina 2007

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Revisão

Tiaki ki tētahi rārangi

I tiakina i:
5

Gene Therapy Used in Cancer Treatment mā Thomas Wirth, Seppo Ylä‐Herttuala

I whakaputaina 2014

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Revisão

Tiaki ki tētahi rārangi

I tiakina i:
6

Cardiovascular Gene Therapy: Past, Present, and Future mā Seppo Ylä‐Herttuala, Andrew H. Baker

I whakaputaina 2017

Whiwhi kuputuhi katoa
Revisão

Tiaki ki tētahi rārangi

I tiakina i:
7

Progress and prospects: hurdles to cardiovascular gene therapy clinical trials mā Marja Hedman, Juha Hartikainen, Seppo Ylä‐Herttuala

I whakaputaina 2011

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Revisão

Tiaki ki tētahi rārangi

I tiakina i:
8

Biology of vascular endothelial growth factors mā Himadri Roy, Shalini Bhardwaj, Seppo Ylä‐Herttuala

I whakaputaina 2006

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Revisão

Tiaki ki tētahi rārangi

I tiakina i:
9

Promoting blood vessel growth in ischemic diseases: challenges in translating preclinical potential into clinical success mā Galina Dragneva, Petra Korpisalo, Seppo Ylä‐Herttuala

I whakaputaina 2013

Whiwhi kuputuhi katoa
Revisão

Tiaki ki tētahi rārangi

I tiakina i:
10

Adenoviral Gene Therapy Vectors in Clinical Use—Basic Aspects with a Special Reference to Replication-Competent Adenovirus Formation and Its Impact on Clinical Safety mā Aleksi J. Leikas, Seppo Ylä‐Herttuala, Juha Hartikainen

I whakaputaina 2023

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Revisão

Tiaki ki tētahi rārangi

I tiakina i:
11

Expression of LDL Receptor, VLDL Receptor, LDL Receptor–Related Protein, and Scavenger Receptor in Rabbit Atherosclerotic Lesions mā Timo P. Hiltunen, Jukka Luoma, T. Nikkari, Seppo Ylä‐Herttuala

I whakaputaina 1998

Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
12

Nucleic Acid–Based Therapies for Atherosclerosis mā Petri I. Mäkinen, Anna‐Kaisa Ruotsalainen, Seppo Ylä‐Herttuala

I whakaputaina 2020

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Revisão

Tiaki ki tētahi rārangi

I tiakina i:
13

Antioxidant Gene Therapy for Cardiovascular Disease mā Anna‐Liisa Levonen, Elisa Vähäkangas, Jonna K. Koponen, Seppo Ylä‐Herttuala

I whakaputaina 2008

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Revisão

Tiaki ki tētahi rārangi

I tiakina i:
14

Growth factor-induced therapeutic angiogenesis and arteriogenesis in the heart?gene therapy mā Jaakko O. Markkanen, Tuomas T. Rissanen, Annukka M. Kivelä, Seppo Ylä‐Herttuala

I whakaputaina 2004

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Revisão

Tiaki ki tētahi rārangi

I tiakina i:
15

Autoantibodies Against Oxidized Low-Density Lipoprotein and Cardiolipin in Patients With Coronary Heart Disease mā Arja T. Erkkilä, Outi Närvänen, Seppo Lehto, Matti Uusitupa, Seppo Ylä‐Herttuala

I whakaputaina 2000

Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
16

Angiogenic gene therapy in cardiovascular diseases: dream or vision? mā Seppo Ylä‐Herttuala, Charles R. Bridges, Michael G. Katz, Petra Korpisalo

I whakaputaina 2016

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Revisão

Tiaki ki tētahi rārangi

I tiakina i:
17

Differential but Complementary HIF1α and HIF2α Transcriptional Regulation mā Nicholas Downes, Nihay Laham-Karam, Minna U. Kaikkonen, Seppo Ylä‐Herttuala

I whakaputaina 2018

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
18

Hypoxia induces microRNA miR‐210 in vitro and in vivo mā Kati Pulkkinen, Tarja Malm, Mikko P. Turunen, Jari Koıstınaho, Seppo Ylä‐Herttuala

I whakaputaina 2008

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
19

Baculoviruses exhibit restricted cell type specificity in rat brain: a comparison of baculovirus- and adenovirus-mediated intracerebral gene transfer in vivo mā P. Lehtolainen, Kristiina Tyynelä, J Kannasto, Kari J. Airenne, Seppo Ylä‐Herttuala

I whakaputaina 2002

Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
20

Challenges in monoclonal antibody-based therapies mā Haritha Samaranayake, Thomas Wirth, Diana Schenkwein, J K Räty, Seppo Ylä‐Herttuala

I whakaputaina 2009

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Revisão

Tiaki ki tētahi rārangi

I tiakina i:

Ngā hua rapu - Seppo Ylä‐Herttuala

Glybera's Second Act: The Curtain Rises on the High Cost of Therapy mā Seppo Ylä‐Herttuala

Endgame: Glybera Finally Recommended for Approval as the First Gene Therapy Drug in the European Union mā Seppo Ylä‐Herttuala

Gene Therapy for Malignant Glioma: Current Clinical Status mā Kalevi Pulkkanen, Seppo Ylä‐Herttuala

Current Status of Cardiovascular Gene Therapy mā Tuomas T. Rissanen, Seppo Ylä‐Herttuala

Gene Therapy Used in Cancer Treatment mā Thomas Wirth, Seppo Ylä‐Herttuala

Cardiovascular Gene Therapy: Past, Present, and Future mā Seppo Ylä‐Herttuala, Andrew H. Baker

Progress and prospects: hurdles to cardiovascular gene therapy clinical trials mā Marja Hedman, Juha Hartikainen, Seppo Ylä‐Herttuala

Biology of vascular endothelial growth factors mā Himadri Roy, Shalini Bhardwaj, Seppo Ylä‐Herttuala

Promoting blood vessel growth in ischemic diseases: challenges in translating preclinical potential into clinical success mā Galina Dragneva, Petra Korpisalo, Seppo Ylä‐Herttuala

Adenoviral Gene Therapy Vectors in Clinical Use—Basic Aspects with a Special Reference to Replication-Competent Adenovirus Formation and Its Impact on Clinical Safety mā Aleksi J. Leikas, Seppo Ylä‐Herttuala, Juha Hartikainen

Expression of LDL Receptor, VLDL Receptor, LDL Receptor–Related Protein, and Scavenger Receptor in Rabbit Atherosclerotic Lesions mā Timo P. Hiltunen, Jukka Luoma, T. Nikkari, Seppo Ylä‐Herttuala

Nucleic Acid–Based Therapies for Atherosclerosis mā Petri I. Mäkinen, Anna‐Kaisa Ruotsalainen, Seppo Ylä‐Herttuala

Antioxidant Gene Therapy for Cardiovascular Disease mā Anna‐Liisa Levonen, Elisa Vähäkangas, Jonna K. Koponen, Seppo Ylä‐Herttuala

Growth factor-induced therapeutic angiogenesis and arteriogenesis in the heart?gene therapy mā Jaakko O. Markkanen, Tuomas T. Rissanen, Annukka M. Kivelä, Seppo Ylä‐Herttuala

Autoantibodies Against Oxidized Low-Density Lipoprotein and Cardiolipin in Patients With Coronary Heart Disease mā Arja T. Erkkilä, Outi Närvänen, Seppo Lehto, Matti Uusitupa, Seppo Ylä‐Herttuala

Angiogenic gene therapy in cardiovascular diseases: dream or vision? mā Seppo Ylä‐Herttuala, Charles R. Bridges, Michael G. Katz, Petra Korpisalo

Differential but Complementary HIF1α and HIF2α Transcriptional Regulation mā Nicholas Downes, Nihay Laham-Karam, Minna U. Kaikkonen, Seppo Ylä‐Herttuala

Hypoxia induces microRNA miR‐210 in vitro and in vivo mā Kati Pulkkinen, Tarja Malm, Mikko P. Turunen, Jari Koıstınaho, Seppo Ylä‐Herttuala

Baculoviruses exhibit restricted cell type specificity in rat brain: a comparison of baculovirus- and adenovirus-mediated intracerebral gene transfer in vivo mā P. Lehtolainen, Kristiina Tyynelä, J Kannasto, Kari J. Airenne, Seppo Ylä‐Herttuala

Challenges in monoclonal antibody-based therapies mā Haritha Samaranayake, Thomas Wirth, Diana Schenkwein, J K Räty, Seppo Ylä‐Herttuala

Ngā utauta rapu:

Ngā marau whai pānga